Tebotelimab [CAS 2245725-04-4]
Partner: MedChemexpress LLC
| CAS No: | 2245725-04-4 |
| Applications: | COVID-19-immunoregulation |
| MW: | N/A |
| Formula: | N/A |
| SMILES: | [Tebotelimab] |
| Purity: | 99.90 |
| Description: | Tebotelimab (MGD-013) is a human IgG4? bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity[1][2][3]. |
| Shipping Conditions: | Ship on dry ice |
| Usage: | Research Use Only |
Insight Biotechnology Ltd reserves the right to change pricing without notice
